Get started
Author

Sylwia Feszak

Observed name: Sylwia Morawska
ORCID: 0000-0003-2966-7565
Observed ORCID: 0000-0003-2966-7565
OpenAlex ID: A5035476507
Mutations in ATM , NBN and BRCA2 predispose to aggressive prostate cancer in Poland
2020 · Dominika Wokołorczyk, Wojciech Kluźniak, et al. · International Journal of Cancer · 48
PDF
PALB2 mutations and prostate cancer risk and survival
2021 · Dominika Wokołorczyk, Wojciech Kluźniak, et al. · British Journal of Cancer · 43
Inherited Variants in BLM and the Risk and Clinical Characteristics of Breast Cancer
2019 · Wojciech Kluźniak, Dominika Wokołorczyk, et al. · Cancers · 27
PDF
Isotretinoin Treatment for Acne Vulgaris: A Five-Year Retrospective Analysis of Clinical and Biochemical Adverse Effects
2025 · Igor Jarosław Feszak, Piotr Brzeziński, et al. · Journal of Clinical Medicine · 19
PDF
BRCA1 and BRCA2 Mutations in Polish Women with Ductal Carcinoma In Situ
2025 · Sylwia Feszak, Igor Jarosław Feszak, et al. · Cancers · 8
PDF
Infant with Parotid Sialoblastoma and Nevus Sebaceous, Treated with Surgery and Adjuvant Chemotherapy
2023 · Radosław Opiła, Sylwia Feszak, et al. · Children · 3
PDF
Association analysis of germline mutations in CHEK2, PALB2, NBN and RECQL with the risk of ductal carcinoma in situ in Polish women
2025 · Sylwia Feszak, Wojciech Kluźniak, et al. · Hereditary Cancer in Clinical Practice · 1
PDF
Unveiling a Dermatological Rarity: The Enigma of Vulvar Intraepithelial Neoplasia Grade III (HSIL) and the Role of p53 in Its Development
2024 · Piotr Brzeziński, Igor Feszak, et al. · Biomedicines · 1
PDF
Borrelial lymphocytoma in a child
2022 · Sylwia Feszak, Igor Jarosław Feszak, et al. · Pediatria Polska · 1
PDF
Works count: 9
Citation count: 150
H-index: 5
I10-index: 4
Year
Topic
Type